CNO Financial Group, Inc. (CNO) Stock Price & How to Invest

CNO Financial Group provides life and health insurance, annuities, and workforce benefits to middle-income and senior consumers across the United States. It reaches customers through a mix of career agents (Bankers Life), worksite and independent distribution (Washington National and Optavise), and direct-to-consumer channels (Colonial Penn, known for its television-advertised life policies). The company reports roughly 3.3 million policies and about $39 billion in total assets, and organizes its business around three main insurance segments plus a fee-based benefits arm.

The investment picture is that of a stable, capital-return-focused insurer that the market has been rewarding. CNO has posted a long streak of new-sales growth (15 consecutive quarters as of Q1 2026), grown operating earnings per share at a double-digit pace, and raised its dividend for 14 straight years while buying back stock. In the second quarter of 2026, revenue was about $1.29 billion and net income about $126 million, with operating EPS of $1.26 against a consensus near $0.97, the fourth consecutive quarter of beating estimates. Trailing revenue has reached about $4.65 billion. As a life-and-health insurer, its results are sensitive to interest rates, investment-portfolio credit quality, and the performance of legacy long-term-care blocks; Treasury yields above 5% this autumn have helped the reinvestment story. Investors typically weigh its still-modest forward valuation (about 11 times) and consistent capital return against the slower structural growth of the middle-income insurance market. Third quarter results are scheduled for October 29, 2026.

CNO carries the typical risks of a life and health insurer. Its investment portfolio is exposed to credit losses, and prolonged low or sharply changing interest rates can pressure spread income and reserve adequacy; rising yields also cut the market value of bonds already held. Legacy long-term-care insurance blocks can require reserve strengthening if claims or assumptions worsen. Quarterly GAAP earnings are volatile (net income swung from about $23 million in Q3 2025 to $126 million in Q2 2026), and analysts expect third quarter operating EPS of about $1.10, below the year-earlier $1.29. Margin compression, adverse mortality or morbidity trends, and regulatory or reserving changes can weigh on earnings. After a roughly 42% one-year gain the stock trades near the analyst mean target of about $54.75 (consensus rating hold), and as a mid-cap insurer it can be more sensitive to sentiment shifts than larger, more diversified peers.

4 analysts publish price targets on CNO, averaging $54.75 against a $54.71 price as of October 2026, or +0.1%. The published targets run from $52.00 to $57.00, a narrow spread, and the ratings split 0 buy, 5 hold, 0 sell. Over the last six months there have been 7 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CNO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on CNO Financial Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Middle-income and senior market focus. CNO targets a large, underserved segment of Americans who are often overlooked by larger insurers and wealth managers. The most optimistic published target, $57.00, assumes this works close to its best case.

The case against. CNO carries the typical risks of a life and health insurer. The most pessimistic target, $52.00, is roughly what CNO is worth if this bites instead.

Read the full bull and bear case on CNO, including what would have to change to break either one. Walnut is not an investment adviser.

No. CNO Financial Group, Inc. (CNO) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CNO Financial Group, Inc.'s investor relations page or your broker.

• Market cap: ~$5.1B
• Revenue (TTM): ~$4.65B, +11.6% YoY in Q2 2026
• Net income (TTM): ~$280M, ~6% net margin
• Operating EPS (Q2 2026): ~$1.26 vs ~$0.97 consensus
• P/E (trailing / forward): ~19x / ~11x
• Price to book: ~2.0x
• Dividend yield: ~1.3% ($0.72 annual)

CNO still trades at a modest forward earnings multiple of about 11 times relative to the broader market, consistent with its profile as a mature, mid-cap insurer, even after a roughly 30% gain in 2026. The trailing GAAP P/E of about 19 looks higher because reported net income includes investment and reserve swings that operating earnings exclude. Third quarter results arrive October 29, 2026, with consensus operating EPS of about $1.10 on roughly $1.01 billion of revenue.

Other names that sit close to CNO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CNO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CNO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CNO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CNO is a value-oriented, dividend-raising insurer serving the underserved middle-income market, with steady sales momentum and four straight quarterly earnings beats offset by interest-rate and long-term-care sensitivity. After a sharp rerating, the shares now sit close to the average analyst target, so the next leg depends more on earnings delivery than on multiple expansion.

Whether CNO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CNO a buy or a sell?, and where the stock could go from here in the CNO stock forecast.

For income investors, whether CNO pays a dividend and how the payout looks is covered in does CNO pay a dividend? And to weigh CNO against a peer, read the full side-by-side comparisons: CNO vs GL and CNO vs PRI.